Although increased height has been associated with osteosarcoma risk in previous epidemiologic studies, to the authors' knowledge the relative contribution of stature during different developmental timepoints remains unclear. Furthermore, the question of how genetic determinants of height impact osteosarcoma etiology remains unexplored. Genetic variants associated with stature in previous genome-wide association studies may be biomarkers of osteosarcoma risk. METHODS: The authors tested the associations between osteosarcoma risk and polygenic scores for adult height (416 variants), childhood height (6 variants), and birth length (5 variants) in 864 osteosarcoma cases and 1879 controls of European ancestry. RESULTS: Each standard deviation increase in the polygenic score for adult height, corresponding to a 1.7-cm increase in stature, was found to be associated with a 1.10-fold increase in the risk of osteosarcoma (95% confidence interval [95% CI], 1.01-1.19; P =.027). Each standard deviation increase in the polygenic score for childhood height, corresponding to a 0.5-cm increase in stature, was associated with a 1.10-fold increase in the risk of osteosarcoma (95% CI, 1.01-1.20; P =.023). The polygenic score for birth length was not found to be associated with osteosarcoma risk (P =.11). When adult and childhood height scores were modeled together, they were found to be independently associated with osteosarcoma risk (P =.037 and P = .043, respectively). An expression quantitative trait locus for cartilage intermediate layer protein 2 (CILP2), rs8103992, was significantly associated with osteosarcoma risk after adjustment for multiple comparisons (odds ratio, 1.35; 95% CI, 1.16-1.56 [P = 7.93×10 -5 and P adjusted =.034]). CONCLUSIONS: A genetic propensity for taller adult and childhood height attainments contributed independently to osteosarcoma risk in the current study data. These results suggest that the biological pathways affecting normal bone growth may be involved in osteosarcoma etiology.
INTRODUCTION
Osteosarcoma is the most commonly diagnosed primary malignant bone tumor, with peak incidence occurring during adolescence. 1 Osteosarcomas frequently arise at sites of rapid bone growth, especially the metaphyses of long bones. These aggressive tumors occur most frequently around the time of puberty, after which the risk declines substantially. 1 Correspondingly, the diagnosis of osteosarcoma tends to occur at younger ages in females compared with males, reflecting their earlier age of peak height velocity. 2, 3 Although the average age at the time of osteosarcoma diagnosis is younger in females, the overall incidence of osteosarcoma is lower in females than in males, possibly related to population-level sex differences in height attainment. 4, 5 These epidemiologic observations suggest that factors involved in osteoblast proliferation during normal bone growth also may be involved in osteosarcoma formation.
A subset of osteosarcoma diagnoses is attributable to heritable cancer predisposition syndromes, [6] [7] [8] [9] with approximately 3.8% of patients estimated to carry known or likely Li-Fraumeni syndrome-associated mutations, 10 and 7% of patients experiencing secondary malignancies suggestive of hereditary cancer syndromes. 11 Epidemiologic research exploring the role of common genetic variations in the predisposition to osteosarcoma has suggested a role for variants in the DNA repair, 12 growth hormone, 3 and telomere maintenance pathways 13 as potential risk factors. However, to the best of our knowledge, only a single genome-wide association study (GWAS) of osteosarcoma risk has been published to date.
14 This GWAS reported 2 osteosarcoma risk loci at 6p21.3 and 2p25.2, but to our knowledge the biologic mechanisms underlying these associations remain unknown.
Cancer September 15, 2018 In addition to male sex, the factor most consistently associated with increased osteosarcoma risk is above-average height. 1, 4, 15 In 1967, Fraumeni observed that children with osteosarcoma were significantly taller at the time of diagnosis compared with a hospital-based control group and suggested that "the origin of at least some of these tumors is a function of skeletal growth rates during childhood and adolescence." 16 Subsequent studies generally have replicated these findings, observing that individuals in the 90th percentile of height are at an increased risk 1 and that height at both the time of diagnosis and 1 year prior are greater in osteosarcoma patients compared with the general population. 17, 18 However, other studies have been less convincing, observing that patients with osteosarcoma had shorter birth length, 19 that age-specific and sex-specific height percentiles were not associated with osteosarcoma risk, 20 that only patients diagnosed during adolescence had elevated heights, 21 and that patients demonstrated no consistent pattern of differences in growth. 22 Recent GWASs investigating the genomic architecture of human height have identified hundreds of variants associated with stature. A recent meta-analysis of GWAS data from >250,000 individuals identified 423 independent loci explaining approximately one-fifth of the heritability for adult height attainment, suggesting several pathways relevant to cancer (eg, WNT/β-catenin and Hedgehog signaling). 23 Another GWAS meta-analysis of nearly 20,000 subjects has identified 6 loci associated with childhood height attainment before the onset of pubertal growth acceleration (ie, the "takeoff phase"), measured at age 10 years in girls and age 12 years in boys. 24 This same consortium identified additional loci associated with birth length, including several that overlapped with genes suggested in adult height attainment. 25 Given that osteoblast proliferation within the context of both normal bone growth and osteosarcomagenesis may rely on shared progrowth pathways, we sought to determine whether genetic determinants of birth length, childhood height, or adult height play roles in osteosarcoma etiology.
We evaluated the individual and combined (ie, as polygenic scores) effects of 416 single-nucleotide polymorphisms (SNPs) associated with adult height attainment, 6 SNPs associated with childhood height attainment, and 5 SNPs associated with birth length in 864 osteosarcoma cases and 1879 controls of European ancestry from 2 independent case-control studies. We further assessed whether there was causal evidence of height affecting osteosarcoma risk using a Mendelian randomization framework. Finally, we investigated whether genetic associations were enriched among certain growth-related pathways, or are modified by subject sex or clinical presentation, to gain further insight into the etiology and progression of this aggressive malignancy.
MATERIALS AND METHODS

California Osteosarcoma Case-Control Study
The study was approved by the institutional review boards at the University of California at Berkeley and the California Department of Public Health. The California Department of Public Health Genetic Diseases Screening Program obtains newborn blood samples from all neonates born within the state for the purpose of disease screening. Remaining bloodspots have been archived at -20°C since 1982 and are available for approved research. We linked statewide birth records (1982-2009) with cancer diagnosis data from the California Cancer Registry (CCR) . Included in this analysis were 207 osteosarcoma cases and 696 controls born in California between 1982 and 2009. Cases were diagnosed with osteosarcoma before age 20 years, as per CCR record. Controls were matched based on birth year, sex, and maternal self-reported race/ethnicity. Detailed characteristics of these subjects have been reported previously, 26 and appear in Supporting Table 1 . The OR represents the osteosarcoma risk associated with an increase of 1 standard deviation (SD) in the polygenic height score, corresponding to approximately 1.7 cm of adult height, 0.5 cm of childhood height, and 0.14 cm of birth length, estimated by multiplying the SD of each polygenic height score (calculated using beta values of standardized height from prior genome-wide association study regression analyses) by the SD of population height in cm averaged between men and women aged ≥20 years for adult height, between boys aged 12 years and girls aged 10 years for childhood height, and between male and female infants from birth to age 2 months for birth length, reported from the National Health and Nutrition Examination Survey data on the US population in 2007 through 2010.
b P values were unadjusted for multiple testing. c Adult polygenic height score excluding SNPs that were in linkage disequilibrium with childhood height SNPs.
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DNA Extraction From California Newborn Bloodspots
Approximately one-third of a 12-mm dried bloodspot was partitioned into 3 uniform segments and placed in a 2-mL microcentrifuge tube before the extraction, performed using the QIAamp DNA Investigator Kit (Qiagen, Valencia, California). Approximately 280 μL of Buffer ATL (Qiagen) and 20 μL of Proteinase K were added to each sample. Samples were vortexed and incubated in a dry-bath shaker at 900 revolutions per minute and 56°C for 1 hour. After incubation, samples were briefly centrifuged and the lysate solution was transferred to a new 2-mL microcentrifuge tube, whereas the solid remnants were discarded. One μL of 1 ng/μL carrier RNA was added to the lysate and then briefly vortexed. Samples were placed in the Qiagen Qiacube automated work station for DNA isolation, yielding a purified DNA sample in buffer ATE.
Genotyping and Quality Control of California Case and Control Specimens
DNA specimens were assigned to genotyping plates using blocked randomization according to case-control status, reported ethnicity, and sex. DNA was genotyped on the Affymetrix Axiom Latino Array (Thermo Fisher Scientific, Waltham, Massachusetts). DNA samples were genotyped on an Affymetrix TITAN system, and raw image files were processed with Affymetrix Genetools.
Duplicate samples (34 samples) had an average genotype concordance of >99%. Call rate filtering for SNPs and samples was performed iteratively as follows: SNPs with call rates <92% were removed, followed by samples with call rates <95%, SNPs with call rates <97%, and samples with call rates <97%. Any SNP displaying a significant departure from Hardy-Weinberg equilibrium P<1.0×10 -5 among controls of European ancestry was excluded. Samples with mismatched reported versus genotyped sex were excluded. We performed identity-by-descent (IBD) analyses using open-source-software PLINK and excluded 1 member of any sample pair that had an IBD proportion >0.18. 27 Using genome-wide SNP data from 1184 phase 3 samples from the International HapMap Project, we performed principal component (PC) analysis using unlinked autosomal biallelic SNPs with an allele frequency >0.05 and removed from the analysis any sample demonstrating evidence of non-European ancestry (>3 standard deviations [SDs] from mean values of Utah residents with Northern and Western European ancestry (CEU) on PCs 1-3) (see Supporting Fig. 1a-b) .
National Cancer Institute/Geisinger Osteosarcoma Data Set
A second osteosarcoma case-control data set was built from dbGaP study accession phs000734. v1.p1 (A Genome-wide Association Study [GWAS] of Risk for Osteosarcoma) and phs000381.v1.p1 (eMERGE Geisinger eGenomic Medicine MyCode Project Controls). Specimens were genotyped on the Illumina OmniExpress array (Illumina Inc, San Diego, California) and underwent quality control filtering as previously described. 13 Briefly, SNPs with call rates <0.98 were removed from analyses. After the removal of poorly performing SNPs, subjects with genotyping call rates <0.97 were removed. Ancestry-informative PCs were calculated using Eigenstrat and HapMap reference samples and the mean values of the first 5 PCs were calculated among HapMap CEU samples. 27 Subjects that fell more than 3 SDs from the mean CEU values on PCs 1-3 were excluded from further analyses (see Supporting Fig. 1c-d) . Because the National Cancer Institute (NCI)/ Geisinger cases were selected in a clinic-based manner and included subjects from hospitals in Italy and Spain, we performed additional PC analyses in these subjects to investigate more cryptic intra-European ancestral differences using Human Genome Diversity Cell Line Panel reference samples (see Supporting Fig. 1e-f) .
After the removal of subjects with non-European ancestry, SNPs with Hardy-Weinberg equilibrium P<1.0×10 -5 among controls were removed. Osteosarcoma cases and controls from the CCR and NCI/Geisinger data sets were compared and both duplicated and cryptically related samples were excluded from the NCI/Geisinger data set (IBD >0.18). A total of 657 nonoverlapping cases of European ancestry and 1183 controls were included in the final NCI/Geisinger data set. Osteosarcoma cases were predominantly children and adolescents (aged <21 years), although individual-level age data were unavailable and the original publication was not restricted to a specific age range. These subjects are a subset of those included in a previous GWAS. 14 Genotype Imputation:
Haplotype phasing was performed with SHAPEIT (version 2.790) 28 and whole-genome imputation was performed using the Minimac3 software 29 with 64,976 human haplotypes from the 2016 release of the Haplotype Reference Consortium used as the imputation reference panel. 30 SNPs with imputation quality (info) scores <0.60 or posterior probabilities <0.90 were excluded to Cancer September 15, 2018 remove poorly imputed SNPs, as was previously done for the same Axiom array design. 31 Imputation quality metrics for SNPs included in the polygenic scores are presented in Supporting Table 2 , with information scores ranging from 0.76 to 1.0.
Construction of Polygenic Scores and Statistical Analyses
We estimated the association between osteosarcoma risk and weighted polygenic height scores (PHS) (for adult height attainment [PHS adult ], childhood height attainment [PHS child ], and birth length [PHS birth ]), with adjustment for 5 ancestry-informative PCs, sex, and birth year (California data set only) using logistic regression and then combining the results for the California data set and the NCI/Geisinger data set using fixed-effects meta-analysis.
To construct the PHS adult , we selected the most statistically significant SNP from each of the 423 independent height-associated loci reported by Wood et al. 23 Although other large GWAS of height have been performed to date, to the best of our knowledge the next largest was published by the same group, and all subjects in those analyses were a subset of those included in the study by Wood et al. 23, 32 We screened the 423 variants and ensured that no 2 SNPs had a pairwise squared correlation coefficient (R 2 ) ≥0.10. The PHS adult for each individual was calculated as the number of effect alleles (ie, the allele associated with taller stature) at each SNP multiplied by the weight for that SNP (ie, the beta value of standardized height per effect allele reported in previous GWAS regression analyses 23 ) summed across all height SNPs. Among 423 height-associated SNPs, 416 were genotyped successfully or imputed in our osteosarcoma case-control data. To determine the validity of the PHS adult , we assessed its association with adult height among 1183 NCI/ Geisinger control subjects aged ≥21 years, with adjustment for 5 ancestry-informative PCs and sex.
The PHS child was built using 6 independent SNPs that were associated with height at age 10 years in girls and age 12 years in boys at genome-wide statistical significance in Cousminer et al. 24 The PHS birth was built using 5 independent SNPs that were associated with birth length at P<1.0×10 -6 and were successfully replicated in an independent data set at P<.05 (1 variant) or were located within 25 kilobases (kb) of a SNP associated with adult height in a prior GWAS (4 variants), as reported by van der Valk et al. 25 Unfortunately, childhood height and birth length data were unavailable in either the California or the NCI/Geisinger data sets.
None of the height-associated SNPs were located within 1 megabase of a previously identified osteosarcoma risk locus on chromosome 2. However, 1 adult height SNP, rs12214804, was located 152 kb away from a previously identified osteosarcoma risk SNP on chromosome 6 (rs1906953), with an R 2 of 0.046 in HapMap subjects of European ancestry. We therefore performed a sensitivity analysis by excluding rs12214804 from the PHS adult and recalculating its association with osteosarcoma risk.
PHS birth and PHS child were not correlated with each other (R = -0.0026; P =.89), but each was positively correlated with the PHS adult (R = 0.15 [P = 2.2×10 -15 ] and R = 0.15 [P = 1.4x10 -12 ], respectively) due to linkage disequilibrium (LD) between SNPs comprising the models. When we constructed a new reduced PHS adult based on 411 total SNPs (after excluding 5 SNPs linked to those used in constructing the PHS birth variable), correlation between the 2 PHSs disappeared (R = 0.0049; P =.74). Similarly, when we constructed a new reduced PHS adult based on 410 total SNPs (after excluding 6 SNPs linked to those used in constructing the PHS child variable), correlation between the 2 PHSs disappeared (R = -0.012; P =.53). Given the observed correlations between the PHS variables, their associations with osteosarcoma risk are presented without correction for multiple comparisons.
To study the combined effect of multiple PHSs, we performed association analyses with both PHS child and PHS adult as predictors (using the reduced PHS adult based on 410 total SNPs) and osteosarcoma as the outcome using a logistic regression model, adjusting for 5 ancestry-informative PCs, birth year (for the California data set only), and sex.
Prior GWAS analyses of height reported beta estimates as standardized height rather than height in centimeters (cm) per effect allele. For the purposes of interpreting effect sizes, a conversion was made to approximate the height in cm corresponding to each SD of PHS. We calculated this by multiplying the SD of each PHS (for standardized height) by the SD of population height in cm, averaged between boys aged 12 years and girls aged 10 years for childhood height and between men and women aged ≥20 years for adult height in the United States. 33 For sex-stratified analyses, we examined association signals separately in males and females and tested for heterogeneity of effect using the Cochran Q test. We also conducted case-only analyses, assessing whether polygenic scores for height were associated with differences in clinical presentation, including age at diagnosis, Cancer September 15, 2018 tumor location, and the presence of metastasis. Clinical data were available for only the California cases and were coded as previously described. 26 
Mendelian Randomization Analyses
We used an inverse-variance weighted Mendelian randomization approach to assess the causal association between height and osteosarcoma risk using summarized data, 34 repeated for each of the 3 height measures. We also performed sensitivity analyses to address potential issues of invalid Mendelian randomization assumptions using the Mendelian randomization-Egger regression method to assess potential directional pleiotropy 35 and a weighted median approach that provides a consistent estimate when up to 50% of the SNPs used are invalid instruments.
36
Pathway Analysis of Height-Associated SNPs
For each of the 423 SNPs independently associated with adult height attainment in Wood et al, 23 we identified the nearest protein-coding gene in GRCh37. These RefSeq database gene names then were queried in 2 pathway analysis databases: the Kyoto Encyclopedia of Genes and Genomes (KEGG) and the Protein ANalysis THrough Evolutionary Relationships (PANTHER) Classification System. After identifying highly represented biological pathways within the height-associated gene list (KEGG P value ≤.001; PANTHER gene count ≥10), we recalculated the PHS adult , this time reducing the number of SNPs contributing to the model to only those residing within each respective pathway. In this way, we aimed to determine whether any specific biological processes contributing to height attainment were driving the association between PHS adult and osteosarcoma risk.
Single SNP Association Analyses
Single-locus association statistics for imputed and directly genotyped SNPs were calculated using logistic regression in the SNPTESTv2 program, using an allelic additive model and probabilistic genotype dosages. 37 The effect of individual SNPs on osteosarcoma risk was calculated with adjustment for the first 5 PCs from Eigenstrat software. Analyses were performed separately in the California osteosarcoma case-control data set and the NCI/Geisinger case-control data set. Fixed-effects metaanalysis was performed using the META program. 38 In addition to SNPs used to create the PHSs, we also tested 4 SNPs related to other adolescent anthropometric traits, including childhood height in males, pubertal growth, pubertal growth in females, and late pubertal growth. 24 To assess the statistical significance of associations in the single-SNP analyses, a Bonferroni correction was applied for 431 total tests (416 successfully imputed adult height attainment SNPs, 6 childhood height attainment SNPs, 4 related adolescent anthropometric trait SNPs, and 5 birth length SNPs), resulting in a significance threshold of 1.2×10 -4 .
RESULTS
After removing samples with genotyping call rates <97%, individuals demonstrating evidence of non-European ancestry, and cryptically related individuals, a total of 864 osteosarcoma cases and 1879 controls remained for association analyses. This included 207 osteosarcoma cases and 696 controls from the California data set and 657 nonoverlapping osteosarcoma cases and 1183 controls from the NCI/Geisinger data set. Among the 423 SNPs previously reported to be independently associated with adult height attainment, 23 416 were successfully genotyped or imputed in the California and NCI/Geisinger data sets and used to construct the weighted PHS adult , with 410 SNPs used to construct the reduced PHS adult score that is uncorrelated with childhood height. Among the 6 SNPs reported to be associated with childhood height attainment before the pubertal growth spurt and 5 SNPs reported to be associated with birth length, all were successfully genotyped or imputed in both data sets and used to construct weighted PHSs (PHS child and PHS birth , respectively). The PHS adult was found to be strongly positively correlated with adult height attainment in both men (R = 0.33; P = 3.2×10 -20 ) and women (R = 0.37; P = 1.04×10 -17 ) among 1183 NCI/Geisinger control subjects with adult height information available, indicating that it is likely to serve as a robust predictor of adult height attainment. In multivariable logistic regression analyses, each SD increase in the PHS adult was associated with a 1.10-fold increased risk of osteosarcoma (95% confidence interval [95% CI], 1.01-1.19; P = .027) ( Table 1) . Based on the distribution of PHS adult and a conversion factor using reported height statistics of adults in the US population, 33 this result suggests that a 1.7-cm increase in adult height attainment confers an approximately 10% increased risk of osteosarcoma. Sensitivity analyses excluding rs12214804, a variant in weak LD with a previously identified osteosarcoma risk locus, demonstrated no meaningful attenuation of the PHS adult association (P value changed from .027 to .032), suggesting that the osteosarcoma risk variant is not driving the observed association with PHS adult .
Cancer September 15, 2018 In analyses of childhood height attainment, each SD increase in the PHS child was associated with a 1.10-fold increased risk of osteosarcoma (95% CI, 1.01-1.20; P = .023) ( Table 1) . Based on the distribution of PHS child and a conversion factor using reported height statistics of children in the US population, this result suggests that a 0.5-cm increase in childhood height attainment confers an approximately 10% increased risk of osteosarcoma. When PHS child and the reduced PHS adult were modeled together, both retained statistical significance, suggesting that childhood and adult height attainment are independently associated with risk of osteosarcoma (P child = .023 and P adult =.048, respectively) ( Table 1) . No interaction on the log-additive scale was detected between PHS child and PHS adult (P =.98).
In analyses of birth length, each SD increase in the PHS birth was not found to be significantly associated with osteosarcoma risk, although the direction of the association was consistent with that of childhood and adult height (odds ratio [OR], 1.07; 95% CI, 0.99-1.
[P =.11]).
No differences with regard to PCs 1-3 were observed between cases and controls when compared using Student t tests (P>.10). However, 12 cases from the NCI/ Geisinger data set clustered with French and Italian subjects from the Human Genome Diversity Cell Line Panel, without overlapping controls (see Supporting Fig.  1e-f) . Sensitivity analyses excluding these cases did not result in meaningful changes for PHS adult or PHS child (P = .023 and P = .029, respectively), suggesting that ancestry differences are unlikely to drive the associations between height-related variants and osteosarcoma risk.
Analyses of the PHS child and PHS adult variables did not demonstrate any significant interactions between either variable with subject sex (P interaction =.78 and P interaction = .50, respectively), although the effect estimate was slightly higher for PHS adult in male subjects (see Supporting Table 3 ). In case-only analyses of the California subjects, for whom clinical data were available, we did not observe differences in either the PHS child or PHS adult according to the presence of metastatic disease or tumor stage, differentiation, size, or location (long bone of the arm or leg vs another site), or the patient's age at the time of diagnosis.
Both inverse-variance weighted and the weighted median Mendelian randomization estimates of the causal effect of height on osteosarcoma risk are consistent with those obtained by regressing the PHSs on osteosarcoma when scaled to approximate the unit of height corresponding to an increase of 1 SD in the PHS (see Supporting   Table 4 ). However, the Mendelian randomization estimates were not statistically significant (P>.05), except for the adult height inverse-variance weighted estimate (P = .029). No directional pleiotropy was detected for any of the height measures (Mendelian randomization-Egger intercept P>.05) (see Supporting Table 4) .
Querying the 423 genes associated with adult height attainment against the KEGG database identified 2 overrepresented biological pathways: Hedgehog signaling (8 genes) and Wnt signaling (12 genes). The PANTHER database identified 5 gene ontology pathways containing ≥10, including gonadotropin-releasing hormone receptor (18 genes), Wnt signaling (13 genes), cholecystokinin receptor (CCKR) signaling map (10 genes), inflammation mediated by chemokine and cytokine signaling (10 genes), and integrin signaling (10 genes) (see Supporting  Table 5 ). We calculated 7 new PHS adult , each comprised of only those SNPs belonging to genes in the corresponding pathway. Of these 7 pathways, only the PHS adult based on 10 SNPs involved in the CCKR signaling map pathway was found to be associated with risk of osteosarcoma (P =.027) ( Table 2 ). Although the direction of effect again indicated that variants associated with taller height increased the risk of osteosarcoma, none of the 10 SNPs comprising the model was itself associated with osteosarcoma risk at P<.05 (Table 3) . 23 Single SNP analyses identified 22 variants that were nominally associated with osteosarcoma risk at P<.05, one of which was part of the PHS child (see Supporting  Table 6 ) and 21 of which were part of the PHS adult (see Supporting Table 7 ). One of the variants associated with adult height, rs8103992, was found to be significantly associated with osteosarcoma risk after Bonferroni correction for 431 tests (OR, 1.35; 95% CI, 1.16-1.56 [P = 7.93×10 -5 ; P adjusted = .034]). Located in an intergenic region on chromosome 19, rs8103992 is a reported expression quantitative trait locus (eQTL) for the adjacent gene cartilage intermediate layer protein 2 (CILP2) and the downstream gene lysophosphatidic acid receptor 2 (LPAR2). 39 We assessed whether rs8103992 was located within any regulatory loci using the Epigenome Browser and found that it overlapped a putative enhancer in osteoblast cells, as supported by the peaks for DNase I hypersensitivity, H3K27 acetylation, and H3K4 monomethylation in osteoblast cells. 40 The risk allele (A) is predicted to maintain a transcription factor binding site for HNF4 and FOXA2, as well as the chimeric Ewing sarcoma fusion gene product EWSR1-friend leukemia integration 1 transcription factor (FLI1). [41] [42] [43] [44] Assessing all common SNPs (minor allele
Cancer September 15, 2018 frequency [MAF] >0.01) in an 800-kb window centered on rs8103992 revealed a cluster of SNPs located approximately 75 kb away that were in high LD (R 2 >0.60), and which were slightly more significantly associated with osteosarcoma risk in the case-control data in the current study (Fig. 1) . 23 The lead SNP in the region, rs11878202 (OR, 1.35; 95% CI, 1.18-1.55 [P = 1.38×10 -5 ]), is located in an intron of GEM interacting protein (GMIP) and is itself an eQTL for several genes, including CILP2, LPAR2, PBX4, and GMIP.
DISCUSSION
The results of the current study indicate that a genetic predisposition toward taller stature is a risk factor for osteosarcoma. Using 416 SNPs associated with adult height attainment in a recent GWAS of >250,000 subjects, we constructed a PHS that was significantly associated with both adult height and osteosarcoma risk. The current study data suggested a 1.10-fold increase in osteosarcoma risk per SD in PHS, which corresponds to an approximately 1.7-cm increase in stature. This can be rescaled to make direct comparisons with a previous Mendelian randomization study that reported effects sizes per 10-cm increase in genetically predicted height. 45 While the authors observed an approximately 10% increased risk of lung cancer, a 20% increased risk of breast cancer, and a 60% increased risk of colorectal cancer associated with each 10-cm increase in genetically predicted adult height, 45 our rescaled estimate is equivalent to a 75% increase in osteosarcoma risk per 10-cm increase in adult height.
In addition to the observed association between osteosarcoma risk and a genetic predisposition toward taller adult stature, we also observed a significant association with a genetic predisposition toward taller childhood stature before the takeoff phase of the pubertal growth spurt. It is interesting to note that when the polygenic scores for childhood and adult height attainment were The OR represents the osteosarcoma risk associated with an increase of 1 standard deviation in the polygenic height score for variants belonging to each biologic pathway identified from the height-associated gene list.
b P values were unadjusted for multiple testing. The OR corresponds to the effect of each additional copy of the effect allele, previously associated with adult height, on risk of osteosarcoma.
Cancer September 15, 2018 modeled together, both scores retained statistical significance, suggesting that childhood and adult height attainment are independently associated with the risk of osteosarcoma. This addresses a question that previous observational studies have been poorly suited to answer due to the high correlation between childhood and adult height. Because our childhood and adult height variables were based on genetic polymorphisms rather than physical measurements, there was no correlation noted between these variables after removing SNPs in LD.
The independent effects of childhood height and adult height observed in the data from the current study appear plausible given that up to 20% of adult stature is obtained after childhood during the pubertal growth spurt. 46 Because childhood height captures prepubertal growth, and adult height in addition captures pubertal growth, it is possible that our observed associations reflect the seperate effects of prepubertal and pubertal growth on osteosarcoma risk. This perhaps is logical, considering that a majority of patients with osteosarcoma are diagnosed before they reach adult height, many even before reaching puberty. 4 In single SNP analyses, only rs8103992 was found to be significantly associated with osteosarcoma risk after Bonferroni correction. This SNP, previously associated with adult height attainment, is a known eQTL for the nearby genes CILP2 and LPAR2. 39 It is interesting to note that the risk (A) allele is associated with taller stature and reportedly preserves a transcription factor-binding motif for the chimeric Ewing sarcoma fusion gene product EWSR1-FLI1, 41, 42, 47 suggesting that this SNP may promote bone growth in both healthy and malignant contexts. Although SNPs in CILP2 previously have been associated with adult height attainment and cholesterol levels, 23, 48 to the best of our knowledge they have not been reported to influence anthropometric traits in children. However, a recent epigenome-wide study of body composition in preschool children identified CpGs in CILP2 that were significantly associated with both body mass index and fat-free mass index. 49 Thus, the relationship between genetic and epigenetic variation in CILP2, body composition in children and adults, and future occurrence of disease merits further attention in longitudinal studies.
We used 2 approaches to assess the relationship between height and osteosarcoma risk in this study: 1) estimating the association between the polygenic score for height and osteosarcoma risk; and 2) estimating Figure 1 . Association between single-nucleotide polymorphisms (SNPs) and the risk of osteosarcoma in an extended region of chromosome 19p13.11 (chr19) previously associated with adult height attainment. Genotypes include both "on array" SNPs and additional SNPs imputed as described. A recent genome-wide association study of adult height attainment identified rs8103992 (purple diamond shape) as the lead SNP in this region, 23 and this was used as 1 of 416 SNPs comprising the polygenic height score. Other SNPs are shown by color, demonstrating their extent of genetic linkage with rs8103992. The SNP found to be most significantly associated with the risk of osteosarcoma, rs11878202, is located in an intron of GEM interacting protein (GMIP). The recombination rate, genetic position, and locations of nearby genes are indicated. Mb indicates megabase.
Cancer September 15, 2018 the causal effect of height on osteosarcoma risk using Mendelian randomization. Although the 2 approaches address similar questions of identifying the link between height and osteosarcoma, the estimates obtained from the 2 approaches have different interpretations. 50 The former, an estimate of osteosarcoma risk associated with height-related genetic variants, aims more generally to determine common biological mechanisms between the 2 phenotypes whereas the latter, an estimate of osteosarcoma risk due to height, requires that additional assumptions be satisfied for the estimate to be valid. The Mendelian randomization assumptions are: 1) the SNPs used as instrumental variables are associated with the phenotype of interest (ie, height); 2) the SNPs are not associated with confounders that influence both height and osteosarcoma risk; and 3) the SNPs are associated with osteosarcoma only through their effects on height. 51 The first Mendelian randomization assumption is likely valid for the SNPs used for adult height because the PHS adult was found to be highly correlated with height in the Geisinger controls and explained approximately 4.9% of the variation in adult height attainment after controlling for sex (F-statistic = 140.9). We did not have childhood height or birth length data available to assess the performance of the PHS child or PHS birth , and the percentage of variation explained by these variants generally was not reported in the prior GWAS. 24, 25 However, among the 5 SNPs used for the PHS birth , one had a reported percentage of variance explained of 0.05%, 25 suggesting that the 5-SNP birth length polygenic score is likely not a strong instrumental variable under a Mendelian randomization framework. By carefully excluding individuals with non-European ancestry, balancing cases and controls by ancestry, and adjusting for ancestry-informative PCs in all analyses, inflation of test statistics due to population stratification has likely been controlled, thereby addressing a potential violation of the second assumption. Pleiotropy, wherein a SNP impacts osteosarcoma risk through mechanisms beyond its effect on height, may contribute to the association between stature and osteosarcoma risk. Although Mendelian randomization-Egger regression analyses demonstrated no evidence of directional pleiotropy, 35 the method still is susceptible to bias if multiple variants are associated with the same confounder. Furthermore, although we observed estimates of similar direction and magnitude between the polygenic score association approach and the Mendelian randomization approach, only the inverse-variance weighted approach for adult height reached statistical significance (P<.05), suggesting that caution is warranted when making a causal interpretation between height and osteosarcoma risk. Therefore, we interpret the results of the current study more generally that genetic predisposition to taller stature is a risk factor for osteosarcoma.
Prior literature has suggested that the greater incidence of osteosarcoma in males is attributable to population-level sex differences in height attainment. 4, 5 Associations with the polygenic scores did not appear to differ significantly between males and females, suggesting that the osteosarcoma risk attributable to genetic determinants of height is not sex specific and that a 1.7-cm increase in adult height confers approximately the same magnitude of osteosarcoma risk in men as in women. However, given that men achieve a taller average stature than women, this also suggests that the absolute risk of osteosarcoma will be higher in men than in women despite the risk associated with a per-unit increase in genetic height being approximately the same. It also is possible that the per-unit increase in height has a greater effect on osteosarcoma risk in males compared with females, as previously suggested, 1 but that this effect is not captured by the genetic determinants of height investigated in the current study.
To our knowledge, the issue of whether genetic variation associated with increased height impacts the risk of osteosarcoma via upregulation of shared progrowth pathways or via independent mechanisms is not clear, but evidence suggests that these phenotypes have overlapping genetic determinants. Our pathway-based analyses did not identify a subset of height-associated SNPs that clearly were driving the observed association between the PHS adult and osteosarcoma risk, although a 10-SNP model limited to variants involved in the CCKR signaling map pathway was associated with risk. This finding was intriguing because CCKR signaling is the process that regulates gastrin expression, and gastrin overexpression has been shown to accelerate bone turnover rates in murine models. 52 Overall, the results of the current study align well with a pleiotropic hypothesis wherein osteoblast proliferation is regulated by shared mechanisms within the contexts of both normal bone growth and osteosarcomagenesis. Because height is not a classically modifiable risk factor, the current study findings primarily serve to elucidate the genetic and biological factors linking height and cancer risk rather than to guide specific public health recommendations. In conclusion, the results herein demonstrate that genetic predisposition toward taller childhood and adult stature contributes independently
Cancer September 15, 2018 to osteosarcoma risk, suggesting that the biological pathways affecting normal bone growth also are involved in osteosarcoma etiology. 
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